About this archived opportunity

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Distinctive Features: · This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms. · Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.

Related opportunities

• DoW Breast Cancer, Transformative Breast Cancer Consortium AwardDefense Health Agency Contracting Activity - DHACA·Closes in 58 days
• DoW Breast Cancer, Breakthrough Award Level 3Defense Health Agency Contracting Activity - DHACA·Closes in 58 days
• DoW Breast Cancer, Breakthrough Award Level 4Defense Health Agency Contracting Activity - DHACA·Closes in 58 days
• DoW Ovarian Cancer, Clinical Trial AwardDefense Health Agency Contracting Activity - DHACA·Closes in 59 days
• DoW, Ovarian Cancer, Investigator-Initiated Research AwardDefense Health Agency Contracting Activity - DHACA·Closes in 59 days
• DoW Prostate Cancer, Idea Development AwardDefense Health Agency Contracting Activity - DHACA·Closes in 30 days